GHK-Cu vs KPV
GHK-Cu is the copper(II) complex of glycyl-L-histidyl-L-lysine, an endogenous human plasma tripeptide with a research record reaching back to 1988 and a small, mixed set of controlled human trials. KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, alpha-MSH(11-13), whose evidence base is entirely preclinical and concentrated in rodent gut inflammation and keratinocyte protection. Both are three residues long, both are promoted for inflamed or damaged skin, and both appear in the same recent reviews of short peptides, which is why they are so often set against each other. No published experiment has tested them in the same model, at the same concentrations or against the same endpoints, and neither has been used as a comparator for the other. Two narrative reviews, published in 2025 and 2026, discuss both without comparing them, and they are the entire body of literature that engages the pair.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No study has compared GHK-Cu and KPV directly, in vitro or in vivo, and searches of PubMed and Europe PMC returned no experiment containing arms for both. The two publications that engage both are reviews. A 2025 comprehensive review of tripeptides in wound healing and skin regeneration treated GHK as the most studied tripeptide in the field, describing GHK-based formulations, including nanoparticle conjugates and hydrogels, as enhancing fibroblast migration, extracellular-matrix remodelling and collagen and elastin synthesis, while listing KPV among short peptides delivered from mucoadhesive hydrogels with anti-inflammatory and antibacterial activity; the two were tabulated in parallel rather than tested against each other. A 2026 narrative review of therapeutic peptides in aesthetic, metabolic and endocrine practice grouped both under regenerative and tissue-repair peptides, describing GHK-Cu as a copper-binding tripeptide used in dermatological topical formulations and KPV as an emerging alpha-MSH-derived tripeptide taken up through the PepT1 transporter. Any comparison between them therefore rests on separate studies using different cell types, tissues and endpoints.
The 2 publications that cover both
- 01Review2025
Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review
Adnan SB, et al. · Int J Med Sci · narrative review of tripeptides in wound healing and skin regeneration, covering GHK and GHK-Cu formulations alongside KPV, KdPT and other short peptides, with comparison against larger peptides including LL-37
The review described GHK as the best-studied tripeptide in wound repair, and reported that GHK-based formulations including nanoparticle conjugates, hydrogels and the clinical derivatives TriHex and TriHex 2.0 enhanced fibroblast migration, extracellular-matrix remodelling, collagen and elastin synthesis and wound closure. KPV appeared as a peptide incorporated into in situ mucoadhesive hydrogels, where it reduced inflammation, showed activity against methicillin-resistant Staphylococcus aureus and promoted tissue regeneration. The authors noted that optimising outcomes in chronic wounds remained an unmet challenge, and ran no comparison between the two peptides.
- 02Review2026
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Renke G, Chinellato L · Int J Mol Sci · narrative review of 106 articles on therapeutic peptides in metabolic, endocrine and aesthetic practice, with a section on regenerative and tissue-repair peptides
The review grouped GHK-Cu and KPV together among regenerative and tissue-repair peptides. GHK-Cu was described as a copper-binding tripeptide used in topical dermatological formulations, with reported targets including skin and corneal healing, gastric ulcer regeneration and skin anti-ageing. KPV was described as an alpha-MSH-derived anti-inflammatory tripeptide taken up through PepT1 in intestinal epithelial and T cells, reducing cytokine expression and disease severity in preclinical colitis models. The review reported no comparative data and stated that further study was required before most of the peptides it covered could be used safely in humans.
Side by side.
| GHK-Cu | KPV | |
|---|---|---|
| Evidence maturity | Early clinical | Preclinical only |
| Studies cited here | 15 | 15 |
| Published 2023 or later | 10 | 6 |
| Newest paper | 2026 | 2026 |
| Sequence and origin | Glycyl-L-histidyl-L-lysine complexed with copper(II). GHK is an endogenous constituent of human plasma that binds copper with high affinity, so the peptide has a described physiological role independent of any product. | Lysine-proline-valine, the C-terminal three residues of alpha-melanocyte-stimulating hormone. The parent hormone is endogenous; the free tripeptide is described as its shortest anti-inflammatory fragment. |
| Mechanism as described in the literature | Copper binding and transport, with stimulation of collagen and glycosaminoglycan synthesis in cultured fibroblasts and gene-expression work reporting broad modulation of extracellular-matrix, antioxidant and inflammatory programmes. | Uptake into intestinal epithelial and immune cells through the PepT1 di/tripeptide transporter, followed by suppression of NF-kappaB and MAPK signalling and reduced pro-inflammatory cytokine output. |
| Size of the evidence base | Fifteen studies in this library: six human clinical, one systematic review, four in vitro, two animal in vivo and two reviews, spanning 1988 to 2026. | Fifteen studies: ten animal in vivo, three in vitro and two reviews, spanning 2003 to 2026, with no human study of any kind. |
| Human data | Present but thin and inconsistent. A 2026 PRISMA systematic review searching from database inception located 20 eligible studies, 18 preclinical and 2 randomised controlled trials, and the two largest randomised trials of topical copper tripeptide, in venous stasis ulcers and on CO2 laser-resurfaced skin, found no significant benefit on their objective endpoints. | None. No human clinical trial of KPV has been published for colitis, wound healing, skin inflammation or any other indication. |
| Best-characterised finding | Stimulation of collagen synthesis in cultured fibroblasts across a picomolar to nanomolar dose-response, first reported in 1988 and repeatedly cited since. | PepT1-mediated uptake reducing intestinal inflammation in two mouse colitis models, reported in 2008, and reduction of tumour burden in a murine colitis-associated cancer model in 2016. |
| Tissue focus of the primary work | Skin and its appendages: dermal fibroblasts, keratinocyte models of atopic dermatitis, scalp and scar studies, wound healing, with additional work in silicosis and in Caenorhabditis elegans. | The gastrointestinal tract, principally colitis and colitis-associated cancer, with a smaller body of keratinocyte and oral mucositis work and one traumatic brain injury experiment. |
| Evidence maturity and recency | Early clinical and active, with in vitro, animal, formulation and systematic-review publications appearing in 2025 and 2026. | Preclinical only, and active, though much of the 2024 to 2026 output is formulation science or unrelated metabolic cell-culture work rather than new pharmacology in the marketed use. |
| Basis of most marketing claims | Extrapolation from in vitro collagen and gene-expression data to topical cosmetic outcomes that the controlled human trials did not confirm. | Extrapolation from rodent colitis experiments, most of them using engineered delivery vehicles rather than free peptide, to human use of the unformulated tripeptide. |
And what it does not.
The published literature does not establish how these two tripeptides compare, because no experiment has ever run them together. What it does establish is that they are studied for different things. GHK-Cu has a long in vitro and animal record in skin, a handful of controlled human trials whose largest examples were negative on their objective endpoints, and a 2026 systematic review that found only two randomised trials of the peptide as a standalone aesthetic intervention. KPV has a consistent preclinical mechanism in gut inflammation, replicated across several rodent colitis models, and no human study at all. Neither has an established dose-response for a topical effect in humans, and for KPV even the route by which it might reach human skin is undescribed. The reviews that name both place them in the same category of short peptides with promising preclinical data and insufficient clinical validation, which is a fair summary of where the comparison currently rests.
Common questions.
- Have GHK-Cu and KPV been tested against each other in a wound model?
No. Searches of PubMed and Europe PMC returned no experiment with arms for both peptides, in cell culture, in ex vivo tissue or in animals. The two publications that mention both are narrative reviews of short peptides, which tabulate each separately. Their appearance in the same review reflects shared membership of a peptide class rather than any measured difference in potency, permeation or wound-closure rate between them.
- What did the 2025 tripeptide review report about each peptide?
It treated GHK as the most studied tripeptide in wound healing, reporting that GHK-based formulations, including nanoparticle conjugates, hydrogels and the TriHex derivatives, enhanced fibroblast migration, extracellular-matrix remodelling, collagen and elastin synthesis and wound closure. KPV appeared as a peptide incorporated into in situ mucoadhesive hydrogels, with anti-inflammatory activity, antibacterial effect against methicillin-resistant Staphylococcus aureus and promotion of tissue regeneration. The review compared tripeptides as a class against larger peptides rather than against one another.
- Does either tripeptide have controlled human evidence in skin?
Only GHK-Cu, and it is limited. A 1992 evaluator-blinded randomised trial in venous stasis ulcers and a 2006 randomised trial after CO2 laser resurfacing both used topical copper tripeptide and found no significant benefit on their objective endpoints. A 2026 systematic review located only two randomised controlled trials of GHK-Cu as a standalone aesthetic intervention. KPV has no published human trial in dermatology or in any other field.
- Why does one of the two carry a copper ion?
GHK binds copper(II) with high affinity through its histidyl-lysine motif, and the complex, rather than the free peptide, is the form studied in most of the dermatological literature; copper transport and chelation are part of the proposed mechanism. KPV contains no metal-binding motif of that kind and is studied as a free tripeptide or embedded in a delivery vehicle. The two therefore differ in composition, not only in sequence.
- Do the two peptides act on the same kind of inflammation?
The literatures describe different settings. KPV work is dominated by innate and adaptive immune activity in the intestine, where transporter-mediated uptake precedes suppression of NF-kappaB and MAPK signalling. GHK-Cu work is dominated by dermal remodelling, with anti-inflammatory and antioxidant gene-expression changes reported alongside collagen synthesis. No study has measured both peptides against the same inflammatory endpoint, so the extent of overlap is unknown.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.